Clinical Trial

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Study acronym: O-ICE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2015-03-18; most recent amendment 2025-08-07.
Trial Details
NCT Number NCT02393157
Lead Sponsor New York Medical College
Collaborators: Roswell Park Cancer Institute
Conditions Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
Enrollment 25 participants
Start Date 2015-08-21
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-08